Literature DB >> 23124613

Downregulation of LRIG1 expression by RNA interference promotes the aggressive properties of glioma cells via EGFR/Akt/c-Myc activation.

Ruifan Xie1, Hai Yang, Qungen Xiao, Feng Mao, Suojun Zhang, Fei Ye, Feng Wan, Baofeng Wang, Ting Lei, Dongsheng Guo.   

Abstract

The LRIG1 [leucine-rich repeats and immunoglobulin-like domains (LRIG)] gene is not universally downregulated in human cancers, and its role in tumorigenesis and the development of glioma has not been well addressed. In this study, we used short hairpin RNA (shRNA)-triggered RNA interference (RNAi) to block LRIG1 gene expression in the GL15 human glioma cell line. Specific downregulation of LRIG1 by shRNA resulted in significantly enhanced capabilities of proliferation, inhibition of apoptosis and invasion in the GL15 cells. LRIG1 repression induced marked activation of epidermal growth factor receptor (EGFR), protein kinase B (Akt) and c-Myc signaling molecules. Our results demonstrated that RNAi against LRIG1 may effectively downregulate LRIG1 gene expression. LRIG1 functions as a tumor suppressor in the pathogenesis of glioma via EGFR/Akt/c-Myc activation.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23124613     DOI: 10.3892/or.2012.2102

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  16 in total

1.  MicroRNA-19a promotes glioma cell growth by repressing LRIG1.

Authors:  Ling-Min Shao; Ji-An Yang; Yue-Fei Wang; Peng Wu; Ji-Qiang Li; Qian-Xue Chen
Journal:  Int J Clin Exp Med       Date:  2014-12-15

2.  MicroRNA-590-3p enhances the radioresistance in glioblastoma cells by targeting LRIG1.

Authors:  Long Chen; Wenhua Wang; Shengqiang Zhu; Xuegang Jin; Jian Wang; Jianfang Zhu; Youxin Zhou
Journal:  Exp Ther Med       Date:  2017-06-28       Impact factor: 2.447

Review 3.  The LRIG family: enigmatic regulators of growth factor receptor signaling.

Authors:  Catalina Simion; Maria Elvira Cedano-Prieto; Colleen Sweeney
Journal:  Endocr Relat Cancer       Date:  2014-09-02       Impact factor: 5.678

4.  LRIG1 inhibits hypoxia-induced vasculogenic mimicry formation via suppression of the EGFR/PI3K/AKT pathway and epithelial-to-mesenchymal transition in human glioma SHG-44 cells.

Authors:  Xi Zhang; Qian Song; Chunyan Wei; Jianqiang Qu
Journal:  Cell Stress Chaperones       Date:  2015-04-10       Impact factor: 3.667

5.  Targeting LRIG2 overcomes resistance to EGFR inhibitor in glioblastoma by modulating GAS6/AXL/SRC signaling.

Authors:  Minhai Dong; Qungen Xiao; Jinyang Hu; Fangling Cheng; Po Zhang; Weifeng Zong; Qiaoying Tang; Xiaopeng Li; Feng Mao; Yue He; Xingjiang Yu; Feng Wan; Ting Lei; Dongsheng Guo; Baofeng Wang
Journal:  Cancer Gene Ther       Date:  2020-01-28       Impact factor: 5.987

6.  The up-regulation of LRIG1 expression inhibits the proliferation, apoptosis and invasion of glioma cells.

Authors:  Zhiyong Zhang; Yuanyuan Wang; Xianxing Wang; Hongguang Zhang; Shuai Wang
Journal:  Am J Transl Res       Date:  2022-02-15       Impact factor: 4.060

Review 7.  LRIG1, a regulator of stem cell quiescence and a pleiotropic feedback tumor suppressor.

Authors:  Yibing Ji; Rahul Kumar; Abhiram Gokhale; Hseu-Ping Chao; Kiera Rycaj; Xin Chen; Qiuhui Li; Dean G Tang
Journal:  Semin Cancer Biol       Date:  2021-01-18       Impact factor: 17.012

8.  Soluble LRIG2 ectodomain is released from glioblastoma cells and promotes the proliferation and inhibits the apoptosis of glioblastoma cells in vitro and in vivo in a similar manner to the full-length LRIG2.

Authors:  Qungen Xiao; Yihu Tan; Yang Guo; Hongkuan Yang; Feng Mao; Ruifan Xie; Baofeng Wang; Ting Lei; Dongsheng Guo
Journal:  PLoS One       Date:  2014-10-29       Impact factor: 3.240

9.  Methylation-induced silencing of maspin contributes to the proliferation of human glioma cells.

Authors:  Liang Xu; Hongyuan Liu; Ju Yu; Zhongyong Wang; Qing Zhu; Zongping Li; Qi Zhong; Shuyu Zhang; Mingqi Qu; Qing Lan
Journal:  Oncol Rep       Date:  2016-05-04       Impact factor: 3.906

10.  LRIG1 as a potential novel marker for neoplastic transformation in ocular surface squamous neoplasia.

Authors:  Maho Nagata; Takahiro Nakamura; Chie Sotozono; Tsutomu Inatomi; Norihiko Yokoi; Shigeru Kinoshita
Journal:  PLoS One       Date:  2014-04-07       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.